Simon Joyeux

Managing Director
20+ years of M&A experience 
Deep expertise in financial due diligence
New York
@alvarezmarsal
LinkedIn
Copied!
Simon Joyeux is a Managing Director with Alvarez & Marsal Transaction Advisory Group in New York. He specializes in financial and accounting diligence. His primary areas of concentration are value drivers and deal negotiation. Mr. Joyeux has worked with clients in healthcare and life sciences.

With more than 20 years of mergers and acquisitions experience, Mr. Joyeux has been involved in over 300 financial diligence projects for private equity and corporate clients.

Mr. Joyeux’s notable assignments include platform, add-on, chapter 11 acquisitions, take-private, private investment in public equity deals, mergers, Reverse Morris Trust transactions and debt offerings.

Prior to joining A&M, Mr. Joyeux spent 20 years with Ernst & Young’s Strategy and Transaction group in New York, where he most recently served as Partner. As Partner, he led the U.S. east strategy and transaction health sciences and wellness market.

Mr. Joyeux earned a master’s degree in finance and accounting from ESSEC Business School. He is a New York certified public accountant.

Insights By This Professional

Historically, large healthcare and life sciences corporations have focused deal activity on a breadth of diverse assets. However, the landscape is undergoing significant transformation as businesses shift to rationalize their portfolios and invest in fewer core areas.
The MedTech manufacturing landscape is entering a pivotal phase.
Alvarez & Marsal is proud to release the 2025 Global Biopharmaceutical M&A and VC Insights Report.
A&M is pleased to present a copy of our 2025 Health of the Life Sciences Industry Report.
Latest insights The latest insights from Simon Joyeux's team
Press Releases
Alvarez & Marsal’s Private Equity Performance Improvement (PEPI) team just released the 2026 North America Value Creation Report: Operational Alpha in North America: Closing the Diligence-to-Execution Gap, based on input from 100 private equity investors, operating partners, and PE-backed executives across North America.